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the treatment of newly diagnosed EWING
sarcoma family of tumours – EURO EWING
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Abstract
Background: Although there have been multiple randomised trials in newly diagnosed Ewing sarcoma family of
tumours (ESFT) and these have been conducted over many years and involved many international cooperative groups,
the outcomes for all stages of disease have plateaued. Internationally, the standard treatment of ESFT is not defined,
and there is a need to add new agents other than conventional chemotherapy to improve outcomes. This trial will
compare two different induction/consolidation chemotherapy regimens: (1) vincristine, ifosfamide, doxorubicin and
etoposide (VIDE) induction and vincristine, actinomycin D, ifosfamide or cyclophosphamide, or busulfan and mephalan
(VAI/VAC/BuMel) consolidation and (2) vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE)
induction and ifosfamide and etoposide, vincristine and cyclophosphamide, vincristine, actinomycin D and ifosfamide,
or busulfan and mephalan (IE/VC/VAI/BuMel) consolidation (randomisation 1, or R1). A second randomisation (R2) will
determine whether the addition of zoledronic acid to consolidation chemotherapy, as assigned at R1, is associated
with improved clinical outcome.
Methods: EURO EWING 2012 is an international, multicentre, phase III, open-label randomised controlled trial. There are
two randomisations: R1 and R2. Patients are randomly assigned at two different time points: at entry to the trial (R1)
and following local control therapy (R2). The primary outcome measure is event-free survival. The secondary outcome
measures include overall survival, adverse events and toxicity, histological response of the primary tumour, response of
the primary tumour, regional lymph nodes or metastases (or both), and achievement of local control at the end of
treatment.
Discussion: This study will establish which is the “standard regimen” of chemotherapy, taking into account both
clinical outcomes and toxicity. This will form the chemotherapy backbone for future interventional studies where we
may want to add new targeted agents. It will also determine the role of zoledronic acid in conjunction with the
separate EE2008 trial. Any trial in ESFT needs to take into account the rarity of the tumour and consider that
international cooperation is needed to provide answers in a timely manner.
Trial registration: Registered with EudraCT number 2012-002107-17 on 26 February 2012. Registered with ISRCTN
number 92192408 on 4 November 2013.
Keywords: Ewing sarcoma family of tumours, Randomised controlled trial
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Background and Rationale
The Ewing sarcoma family of tumours (ESFT) usually
arise in skeletal sites in children and young people and
consist of small round malignant cells that may exhibit
varying degrees of neural differentiation. ESFT are char-
acterised by a re-arrangement involving chromosome 22,
and 11;22 translocation is detectable in more than 95%
of cases [1–7]. The gene rearrangement results in the
production of a transcription factor (in the majority,
EWS-FLI1 transcription).
Most ESFT arise in bony sites. Staging procedures
identify about 30% of patients with detectable metastases
at diagnosis. Since chemotherapy was introduced rou-
tinely in the 1970s, cure rates have dramatically
improved. With current multimodal programmes, in-
cluding combination chemotherapy, surgery and radio-
therapy, the 5-year survival rate for localised ESFT is
about 65% with chemotherapy regimens including acti-
nomycin D, doxorubicin, etoposide, cyclophosphamide,
vincristine and ifosfamide. Using different doses and
schedules of administration, ESFT with lung-only metas-
tases treated with conventional chemotherapy experi-
ence a 3-year event-free survival (EFS) of about 30%,
while for those patients with disseminated disease the
prognosis remains very poor, the EURO-E.W.I.N.G. 99
trial demonstrating overall survival (OS) at 3 years of
29% [8].
Internationally, a single standard chemotherapy treat-
ment for ESFT is not defined. The EURO-E.W.I.N.G. 99
trial employed VIDE induction chemotherapy (six cycles
of vincristine, ifosfamide, doxorubicin and etoposide
given about every 3 weeks prior to local control),
followed by risk-adapted randomised treatment of either
vincristine, actinomycin D and ifosfamide or cyclophos-
phamide (VAI/VAC) as consolidation chemotherapy or
high-dose busulfan/melphalan. The toxicity of VIDE in-
duction chemotherapy has been published [9]. In sum-
mary, 12% had grade III or IV stomatitis, 3% had cardiac
left ventricular dysfunction as determined by fractional
shortening, there were five toxic-related deaths out of 851
patients (giving a rate of 0.6%), and grade II, III and IV in-
fections occurred in 40%, 9% and 0.6% respectively. As
yet, the data on second malignant neoplasms (SMNs) have
not been published. But in the EURO-E.W.I.N.G. 99 trial
between 1 September 2001 and 1 September 2005, there
were five SMNs (two leukaemias and three solid tumours)
in the 462 registered patients with localised disease (Ma-
rie-Cécile Le Deley, personal communication).
The other widely used treatment regimen for ESFT,
employed mainly in the US, is from the Children’s Oncology
Group AEWS0031 trial [10]. In that study, patients with
localised ESFT received alternating cycles of vincristine-
doxorubicin-cyclophosphamide and ifosfamide-etoposide
(VDC/IE) as induction chemotherapy and alternating cycles
of ifosfamide-etoposide and vincristine-cyclophosphamide
(IE/VC) as consolidation chemotherapy. There was an up-
front randomisation to compare 3-weekly cycles of this
treatment (standard arm) with 2-weekly cycles (experimen-
tal arm). There was significantly superior EFS of 73% in the
compressed 2-weekly VDC/IE/VC compared with 65% in
the standard arm (P = 0.048) and also improved OS: 83%
and 77% respectively (P = 0.056). This compressed induction
regimen has become the standard regimen for localised
ESFT in the US. In regard to short-term toxicity, there was
one toxic death in the compressed arm B. In arm B, despite
compression of the chemotherapy cycles, stomatitis oc-
curred in 3% and colitis or typhlitis in 0.4% of chemotherapy
cycles. There were no episodes of cardiac left ventricular
dysfunction, and grade III/IV infectious toxicities occurred
as follows: febrile neutropenia 7%, infection with grade 3/4
neutropenia 5%, infection without neutropenia 2% and in-
fection (white cell count unknown) 0.3%. Therefore, a ran-
domisation at diagnosis between VIDE and VAI/VAC
versus VDC/IE/VC is necessary to establish which is the
regimen of choice, taking account of both clinical outcome
(EFS and OS) and toxicity.
Bisphosphonates, a group of compounds that inhibit
bone resorption, have been used for the treatment of bone
metastases in patients with breast cancer, multiple mye-
loma and prostate cancer [11, 12]. In vitro and in vivo data
have also proven the anti-tumour activity of nitrogen-
containing bisphosphonates (N-BPs) against ESFT cells.
The N-BP pamidronate inhibits growth in eight different
ESFT cell lines via inhibition of the mevalonate pathway
[13]. Zhou et al. showed significant inhibition in the devel-
opment of bone metastases after injection of the bisphos-
phonate zoledronic acid in vivo; N-BPs induced apoptosis
and inhibited osseous metastases [14]. Zoledronic acid has
a direct inhibitory effect on the growth of ESFT cells
in vitro which is induced by apoptosis associated with cas-
pase 3 activation and cell cycle arrest in S phase. This ef-
fect was enhanced by alkylating agents. In an in vivo
mouse model, zoledronic acid exerted a strong inhibitory
effect on the growth of bone ESFT and little effect on the
growth of intramuscularly injected ESFT. When combined
with ifosfamide, zoledronic acid exerted synergistic effects
in the soft tissue model: its combination with one cycle of
ifosfamide resulted in an inhibitory effect similar to three
cycles of ifosfamide alone [15].
Although there are no clinical studies of zoledronic
acid in ESFT, except for a single case report of a mul-
tiple relapsed patient responding to zoledronic acid with
third-line chemotherapy, its low toxicity profile with
conventional chemotherapy and the growing body of
evidence for the use of bisphosphonates for the treat-
ment of bone metastases in other cancers described
above provide ample justification to examine the value
of zoledronic acid in a clinical trial.
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Although ESFT are the second commonest malignant
bone tumour in children, adolescents and young adults,
they remain rare tumours (fewer than 70 cases per year
in the UK) and hence any randomised trials must be
international. The EURO EWING Consortium (EEC) is
a partnership of specialists in 15 European countries
working together to improve the outcome in ESFT. The
activities of the EEC are funded by the European Union
for five years and include two clinical trials, translational
research and the strengthening of both patient and pub-
lic involvement and the ethical process. This article pre-
sents the study protocol of the EEC clinical trial:
International Randomised Controlled Trial for the
Treatment of Newly Diagnosed Ewing Sarcoma Family
of Tumours (EURO EWING 2012).
2. Methods
2.1. Design and objectives
EURO EWING 2012 (EE2012) is an international, multi-
centre, phase III, open-label randomised controlled trial.
There are two randomisations: patients are randomly
assigned at entry (randomisation 1, or R1) and then fol-
lowing local control therapy (randomisation 2, or R2).
The trial schema is shown in Fig. 1.
The objective of the induction/consolidation chemo-
therapy R1 is to compare
VIDE as induction chemotherapy and VAI/VAC/
BuMel as consolidation chemotherapy (arm A) with
VDC/IE induction and IE/VC or VAI/BuMel consolida-
tion chemotherapy (arm B) as first-line treatment in all
patients with ESFT with respect to clinical outcome and
toxicity.
The objective of the zoledronic acid randomisation
(R2) is to determine whether the addition of zoledronic
acid to the consolidation chemotherapy assigned at R1 is
associated with improved clinical outcome in patients in
the EE2012 trial.
The third objective is to identify, through the bio-
logical studies embedded in EE2012, informative prog-
nostic biomarkers for assessment of disease status and
response at diagnosis and throughout the disease course.
Whether they are predictive of response to therapy and
may be used to improve stratification of patients and
whether they might predict those patients who may not
tolerate a particular therapy will also be explored.
2.2. Outcome measures
The primary outcome measure is EFS. EFS is defined as
the time from randomisation to first event, where an
event is progression without complete remission, recur-
rence (following complete or partial remission), second
malignancy or death. Patients who do not have an event
by the end of the follow-up period will be censored at
Fig. 1 Trial schema
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their last follow-up date, and patients lost to follow-up
without an event will be censored at the date of their last
consultation.
The secondary outcome measures are the following:
 OS is defined as the time from randomisation to
death, irrespective of the cause. Surviving patients
will be censored at their last follow-up date.
 Adverse events and toxicity, defined by National
Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0
 Histological response of the primary tumour to
induction chemotherapy if surgery is performed as
local control defined as the percentage of viable
tumour cells in the resected primary tumour
specimen
 Response of the primary tumour, regional lymph
nodes and/or metastases, using volume of the whole
primary tumour, diameter of the largest node (or
group if not separate), and number of lung and/or
pleural and other metastases respectively
 Achievement of local control at the end of
treatment as defined by complete surgical resection
following induction chemotherapy, no measurable
disease as assessed by end-of-treatment magnetic
resonance imaging (MRI) or computed tomography
(CT) scan or no increase in measurable residual
tumour over a 6-month period from the end of
treatment
 Growth parameters and jaw/ear osteonecrosis (R2
only) will be assessed by using patient’s height
measured at baseline, treatment and throughout
follow-up for all patients who enter the second
randomisation and who are younger than 18 years of
age at entry. Whether jaw and ear osteonecrosis
occurred will be recorded at the end of or during
treatment for all patients who were randomly
assigned to R2.
Primary tumour volume is assessed by using the fol-
lowing formula: tumour volume = a × b × c × F, where
a, b and c represent the maximum tumour dimensions
(in centimetres) in three planes; F = 0.52 for spherical
tumours or F = 0.785 for cylindrical tumours.
If a pleural effusion is present (with a non-chest wall pri-
mary tumour), it is recorded along with the number of
pulmonary metastases. For chest wall primary tumour,
pleural effusion is considered loco-regional extension.
2.3. Recruitment and randomisation
All eligible patients with ESFT at participating centres
are invited to take part in the trial. EEC partner organi-
sations act as national coordinating centres (NCCs) and
identify participating centres within their country or
countries. The University of Birmingham is the coordin-
ating sponsor and also undertakes the responsibilities of
NCC in the UK. One hundred and ten participating cen-
tres are taking part across 10 countries (Belgium, the
Czech Republic, Denmark, France, Hungary, Ireland, the
Netherlands, Spain, Switzerland and the UK). Patients
enter the trial via R1 and, if following induction chemo-
therapy they fulfil the R2 eligibility criteria, are asked to
participate in R2.
Patients are eligible if all of the trial inclusion criteria
are met and none of the exclusion criteria applies. The
eligibility criteria originally excluded patients with extra-
pulmonary metastatic disease but this was amended in
protocol version 3.0 in September 2016. (The exact date
of implementation of this in each country varies as it
was dependent upon gaining country-specific regulatory
approvals.) The eligibility criteria for R1 and R2 are
shown in Table 1.
For each randomisation, patients are allocated in a 1:1
ratio to the two arms. Randomisation is performed by
staff at participating centres online by using the random-
isation function of the electronic remote data capture
(eRDC) system designed and maintained by the coordin-
ating sponsor.
The R1 randomisation is stratified by age at random-
isation (<14 years or ≥14 years), sex, disease type (ab-
sence of metastases or involvement of lymph nodes only;
lung or pleural metastases only; other metastases), vol-
ume of tumour at diagnosis (<200 mL or ≥200 mL) and
country (the UK, France or other) to ensure that there is
a balance between treatments within the strata defined
by these key prognostic factors.
The R2 randomisation is stratified by allocated treat-
ment in R1, age at R1 randomisation (<14 years or ≥14
years), sex, disease status (localised disease or regional
lymph node involvement of lymph nodes only at diagno-
sis and good risk after induction, localised disease or re-
gional lymph node involvement only at diagnosis and of
lymph nodes only poor risk after induction, lung or
pleural metastases at diagnosis, other metastasis at diag-
nosis), and country (the UK, France or other).
2.4. Trial treatment
Randomisation R1: At trial entry, patients are randomly
assigned to one of the following treatment arms:
 Arm A (VIDE strategy): VIDE induction, VAI/VAC/
BuMel consolidation
Induction chemotherapy: six cycles of VIDE
Consolidation chemotherapy: one cycle of VAI plus
seven cycles of VAC
(good risk localised disease) - R2 VAC.
OR
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One cycle of VAI plus one cycle of BuMel (poor risk
localised disease without contraindication to BuMel)
OR
Eight cycles of VAI (poor risk localised disease with
contraindication to BuMel and/or regional lymph node(s)
involvement and/or metastatic disease) - R2 VAI.
OR
 Arm B (VDC/IE strategy): VDC/IE induction, IE/
VC/VAI/BuMel consolidation
Induction chemotherapy: nine cycles of alternating
VDC and IE.
Consolidation chemotherapy: five cycles of alternating
IE and VC - R2 IE/VC (good risk localised disease and/or
regional lymph node(s) involvement and/or metastatic dis-
ease or poor risk localised disease with contraindication to
BuMel.
OR
One cycle VAI plus BuMel (poor risk localised disease
without contraindication to BuMel).
Randomisation R2: Following induction chemother-
apy, patients who fulfil the eligibility criteria for R2 and
consent to take part in the randomisation will receive
consolidation chemotherapy as allocated at trial entry
and be randomly assigned to receive either:
 Nine cycles of zoledronic acid following the first
cycle of consolidation chemotherapy
OR
 No zoledronic acid
A summary of the enrolment, interventions and the
main assessments is shown in Fig. 2, and a SPIRIT
(Standard Protocol Items: Recommendations for Interven-
tional Trials) checklist is supplied as Additional file 1. The
full schedule of treatments is provided in Additional file 2:
Table S1.
For good risk localised disease patients in arm A, a prag-
matic decision was made to give VAC chemotherapy, as it
is less toxic and requires less time in hospital and is equal
to VAI in terms of outcomes. Local treatment of surgery
or radiotherapy (or both) follows VIDE or VDC/IE induc-
tion chemotherapy, and whenever feasible, surgery pro-
ceeds after cycle 6 of VIDE (arm A) or cycle 9 of VDC/IE
(arm B) on haematological recovery. Decisions on treat-
ment of the primary tumour are individualised as is neces-
sary in this disease. Consolidation chemotherapy is
administered according to the treatment arm randomly
assigned to and whether the patient has regional lymph
node involvement or metastatic disease, or risk group for
localised disease (good risk or poor risk). The definition
localised poor risk and good risk is based on the presence
or absence of a combination of factors, whether there is
resection at diagnosis, tumour volume of at least 200mL,
pre-operative radiotherapy, histological response (≥10% vi-
able tumour), unresectable tumour treated with radiother-
apy alone, and volume of less than 200mL with poor
radiological response (Table 2).
Peripheral blood stem cell (PBSC) mobilisation and
harvesting are recommended after VIDE/VDC/IE
chemotherapy if defined as poor risk localised disease.
PBSC mobilisation and harvesting should be performed
in accordance with institutional guidelines. BuMel treat-
ment is contraindicated for patients where radiotherapy
is required to the central axial sites (spine, sacrum or
pelvis) or when lung or bowel is within the radiotherapy
treatment fields. (The protocol includes specific criteria
Table 1 Inclusion and exclusion criteria
Randomisation 1 Randomisation 2
Inclusion criteria
• Any histologically and genetically confirmed Ewing sarcoma family of
tumours (ESFT) of bone or soft tissue, or round cell sarcomas
‘Ewing’s-like’ but negative for EWSR1 gene rearrangement
(Prior to protocol version 3.0, this read as ‘Histologically confirmed
ESFT of bone or soft tissue, and Localised or pulmonary and/or pleural
metastatic disease’.)
• Age of more than 2 years and less than 50 years
• Randomisation not more than 45 days after diagnostic biopsy/surgery
• Patient medically fit to receive trial treatment
• No prior treatment other than surgery
• Localised tumour
OR
metastatic disease and/or regional lymph node(s) involvement only at
diagnosis and at least partial response of metastases and/or regional
lymph node(s)
(Prior to protocol version 3.0, this read as ‘Localised tumour OR Pulmonary
and/or pleural metastatic disease only at diagnosis and at least partial
response of the lung metastases and no progression of the primary
tumour during induction chemotherapy’.)
• Age of more than 5 years
• Consolidation chemotherapy as per protocol intended
• Medically fit to receive zoledronic acid
Exclusion criteria
• Contra-indication to the treatment in randomisation 1 (R1)
• Second malignancy
• Pregnant or breastfeeding women
• History of dental surgery 6 months preceding the start of zoledronic acid
or planned dental surgery during treatment or within 6 months after the
end of treatment
• History of jaw fracture
• Ewing’s tumour of the maxilla or of the mandible
• Progression of the primary tumour or appearance of new lesions
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Fig. 2 Summary schedule of enrolment, interventions and assessments
Table 2 Definition of poor risk localised disease and indications for busulfan and melphalan (BuMel) high-dose therapy
Case Localised
disease
Resected at
diagnosis
Volume
≥200 mL
Pre-
operative
RT
Histological
response
≥10% viable
tumour
Unresectable
tumour
treated
with RT
alone
Volume <200 mL
but poor
radiological
response i.e.,
<50% regression
with chemotherapy
RT contraindications
to BuMela
Other medical
contraindications
to BuMela
BuMel
recommended
1 N n/r n/r n/r n/r n/r n/r n/r n/r N
2 Y Y N n/r n/r n/r n/r n/r n/r N
3 Y Y Y n/r n/r n/r n/r N N Y
4 Y N N n/r Y n/r n/r N N Y
5 Y N N Y Y n/r n/r N N Y
6 Y N Y N Y n/r n/r N N Y
7 Y N Y Y Y n/r n/r N N Y
8 Y N Y Y N n/r n/r N N Y
9 Y N Y Y n/ab n/r n/r N N Y
10 Y N Y N n/a Y n/r N N Y
11 Y N N N n/a Y Y N N Y
n/a not available, n/r not relevant, RT radiotherapy
aIf response is yes, then high-dose therapy is contraindicated
bFor example, if extracorporeal irradiation of primary tumour is used prior to re-implantation
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regarding doses.) Radiotherapy is recommended to be
given concurrently with consolidation chemotherapy to
the primary site. In patients with pulmonary or pleural
metastatic disease (or both), whole lung radiotherapy is
recommended to be given on completion of consolida-
tion chemotherapy. Radiotherapy to bony metastases
may be given either during consolidation or at the end.
At the end of treatment, an MRI or CT scan should be
performed for patients who received radiotherapy only
as local control and who had residual disease pre-
radiotherapy. If the end-of-treatment scan shows re-
sidual disease, another scan should be performed 6
months after the end of treatment. After treatment, pa-
tients will be followed up with clinical evaluation and
scanning for a minimum of 5 years or until disease pro-
gression or death if sooner. Patient data are collected on
the eRDC by using a series of case report forms, and
follow-up forms are requested annually following the
completion of treatment in order to track patient status.
Patients are also asked to optionally consent to add-
itional biological studies. Participation involves donating
blood samples at multiple time points throughout the
trial and agreeing to any remaining bone marrow and
diagnostic tumour biopsy tissue taken as routine practise
for research purposes.
2.5. Statistical considerations
2.5.1. Randomisation 1
Owing to the rarity of ESFT and a restricted ability to ran-
domly assign sufficient numbers of patients for a conven-
tional design (with two-sided alpha = 0.05 and power =
80%), a Bayesian approach has been taken to the analysis
of R1 which makes no prior assumptions that one chemo-
therapy arm is likely to be better than the other.
With a 5-year accrual period, it should be possible to
randomly assign at least 600 patients across participating
countries. Hence, the minimum sample size is set at 600.
With a minimum of 2 years’ and a maximum of 7 years’
follow-up, there should be at least 150 events.
Non-informative priors will be used, so the posterior
distribution gives Pr (parameter|data) (i.e., the probability
of the treatment effect). The ln (hazard ratio or HR) is
assumed to be normally distributed with variance 4/n,
where n is the total number of events in both arms [16].
Based on the EURO-E.W.I.N.G. 99 data, 3-year EFS is an-
ticipated to be about 70% with VIDE. Table 3 shows, for
600 patients, the probability that one treatment is better
than the other, or not more than 5% worse, for a range of
observed HRs. (An HR of 1.21, or inversely 0.81, repre-
sents about a 5% absolute difference in 3-year EFS.)
The following can be seen:
 With an observed HR of 1.00 (no apparent
difference between the randomly assigned groups in
terms of EFS), there would be probabilities of 10%
or 7% that VDC/IE was actually more than 5%
worse or better respectively than VIDE, with a
cumulative probability of 17% (i.e., within the limits
of clinical acceptability). It would then be reasonable
to base the decision on which regimen is preferable
on toxicity.
 With an observed HR of 0.81 (an observed
improvement of about 5% in EFS with VDC/IE
compared to VIDE), there would be an 8%
probability that the apparently better regimen (i.e.,
VDC/IE) was actually worse (i.e., within the limits of
clinical acceptability).
 With an observed HR of 0.90 (i.e., about a 2.5%
absolute difference in EFS in favour of VDC/IE),
there would be a probability of 25% that the
apparently better regimen was actually worse and a
probability of 3% that it was more than 5% worse
(i.e., at the limit of clinical acceptability).
2.5.2. Randomisation 2
The R2 target is a minimum of 300 patients. An analysis
of R2 will also be carried out in conjunction with the
German Ewing 2008 trial which will have a similar or
greater number of patients, giving a total of about 600
patients. (It is estimated 300 will come from EE2012 and
300 from Ewing 2008.) It is anticipated that it will take
at least 5 years to reach the accrual targets. Patients will
be followed up for progression and death until all trial
objectives have been met. The first main analysis will be
Table 3 Probability of one treatment being better
Observed 3-year EFS Observed HR P (HR <1.00) P (HR <0.81) P (HR
>1.21)VIDE Difference VDC/IE Number of events HR ln (HR)
0.70 0.00 0.70 180 1.00 0.00 0.50 0.07 0.10
0.70 0.05 0.75 165 0.81 −0.21 0.92 0.50 0.00
0.70 −0.05 0.65 195 1.21 0.19 0.09 0.00 0.50
0.70 0.025 0.725 173 0.90 −0.10 0.75 0.23 0.03
0.70 − 0.025 0.675 188 1.10 0.10 0.25 0.02 0.27
EFS event-free survival, HR hazard ratio, VDC/IE vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide, VIDE vincristine, ifosfamide, doxorubicin
and etoposide
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performed once all patients have a minimum of 2
years’ follow-up. For each randomisation, the main
analyses will be intention-to-treat with all patients
analysed in the arm to which they were allocated at
randomisation.
For R2, conventional statistical analyses will be per-
formed: Kaplan–Meier life tables will be constructed
for time-to-event data (with date of randomisation as
reference time point) and arms will be compared by
means of the log-rank test; continuous variables will
be compared across arms by means of t tests or Wil-
coxon tests as appropriate. Multivariable analysis
using Cox regression will be used to adjust for base-
line co-variates as appropriate. Heterogeneity of the
treatment effect according to these factors will be
evaluated. As well as by individual trial, analyses of the
zoledronic acid randomisation will be performed on
the total data set for the two trials combined (with
stratification by trial).
3. Discussion
Internationally, the standard drug treatment of ESFT is
not defined. This study aims to address this and estab-
lish a “standard regimen” of chemotherapy, taking into
account both clinical outcomes (EFS and OS) and tox-
icity. This new standard regimen will form the backbone
of future international studies in ESFT, enhancing op-
portunities for collaboration and thus hastening progress
in improving outcomes from this rare disease. In
addition, this study will provide evidence to establish
whether add-on treatment with a novel agent in this dis-
ease setting, zoledronic acid, is of benefit for patients
with ESFT. Owing to the rarity of the tumour and the
need for timely answers, the study has a pragmatic stat-
istical design, accepting that it is not possible to reach
conventional levels of reliability within a reasonable time
frame, and will recruit patients across several European
countries.
Although these tumours are the second commonest
malignant bone tumour in children, adolescents and
young adults, they remain rare tumours (fewer than 70
cases per year in the UK and 100 in France) and hence
any randomised trial must be international. Setting up
and activating large international trials are complex
processes, involving multiple institutions each with
their own local practises, and require acquiring ap-
provals from numerous regulatory bodies across the
participating countries. However, it is anticipated that
the knowledge, experience and relationships formed
through activating EE2012 internationally will be of
benefit to any future trials established by the EEC and
lead to shorter trial set-up times and therefore quicker
answers to important therapeutic questions.
3.1. Trial status
The trial is open and the first patient was entered in
March 2014. At the time of manuscript submission
(April 2019), 639 and 242 patients had been recruited
into R1 into R2 respectively. The current version of the
protocol is version 5.0, dated 2 June 2017.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-4026-8.
Additional file 1. SPIRIT Checklist.
Additional file 2: Table S1. Summary of treatment details: the
schedules of administration of cycles of chemotherapy and zoledronic
acid.
Abbreviations
BuMel: Busulfan and mephalan; CT: Computed tomography; EE2012: EURO
EWING 2012; EEC: EURO EWING Consortium; EFS: Event-free survival;
eRDC: Electronic remote data capture; ESFT: Ewing sarcoma family of
tumours; HR: Hazard ratio; IE: Ifosfamide and etoposide; MRI: Magnetic
resonance imaging; N-BP: Nitrogen-containing bisphosphonate;
NCC: National coordinating centre; OS: Overall survival; PBSC: Peripheral
blood stem cell; R1: Randomisation 1; R2: Randomisation 2; SMN: Second
malignant neoplasm; VAC: Vincristine, actinomycin D and cyclophosphamide;
VAI: Vincristine, actinomycin D and ifosfamide; VC: Vincristine and
cyclophosphamide; VDC: Vincristine, doxorubicin, cyclophosphamide;
VIDE: Vincristine, ifosfamide, doxorubicin and etoposide
Acknowledgements
We would like to acknowledge members of the EEC and all investigators
and trial staff at participating trial centres. We acknowledge colleagues at
EEC partner organisations University of Birmingham (UoB), Centre Léon
Bérard (CLB), Grupo Español de Investigación en Sarcomas (GEIS), Our Lady’s
Children’s Hospital (OLCH), European Organisation for Research and
Treatment of Cancer (EORTC) who support the trial within their institution.
Authors’ contributions
All authors approved the final manuscript.
Funding
This project has received funding from the European Union’s Seventh
Framework Programme for research, technological development and
demonstration under grant agreement n°602856. The NCC in France, CLB,
receives additional funding from SFCE and Ligue contre le cancer. The
coordinating sponsor (the University of Birmingham, Birmingham, UK) is
funded by Cancer Research UK (grant award reference C5952/A14745). The
funding bodies had no role in the design of the study or collection, analysis,
and interpretation of data or in writing the manuscript.
Availability of data and materials
No data are presented in this manuscript. The materials described can be
obtained by contacting the corresponding author.
Ethics approval and consent to participate
The trial was initially approved by NRES Committee North West - Greater
Manchester Central on 1 February 2013. Since then, there have been 11
approved substantial amendments and the latest version of the protocol
(version 5.0) was approved by the ethics committee on 7 August 2017. This
latest amendment to protocol version 5.0 was to change the consolidation
treatment for patients with poor risk localised disease to VAI plus BuMel,
following the results of the earlier trial EURO-E.W.I.N.G. 99 becoming available
demonstrating this treatment to be superior. Please note that the dates of
ethical approvals are for the submissions made by the coordinating sponsor
in the UK; each NCC has to submit to and gain approvals from the relevant
regulatory bodies in their country (or countries). Central ethical approval for
the whole UK was confirmed by the NRES Committee North West - Greater
Anderton et al. Trials           (2020) 21:96 Page 8 of 9
Manchester Central (reference approval number 12/NW/0827), and we will
not begin recruiting at other centres and in other countries until the relevant
country-specific and local ethical approval has been obtained.
Written informed consent is obtained from each patient or parent/legal
guardian (or both) for each randomisation prior to performing any trial-
related procedure. At trial entry, the patient or parent/legal guardian or both
are also given the option of consenting to the collection, storage and
analysis of additional tumour, blood and bone marrow samples for use in
biological studies associated with the trial but this does not affect whether
they can enter the trial. Patients have the right to withdraw from the study
at any time and for any reason without prejudice to their future medical
care.
With the patient’s consent (and where national legislation/guidance permits),
their full name, date of birth, hospital number, medical practitioner details
and national registry numbers (e.g., National Health Service Number in the
UK) are collected at trial entry to allow long-term follow-up via other health-
care professionals (e.g., patient’s medical practitioner) and national cancer
registries. Personal data recorded on all documents are regarded as strictly
confidential and are handled and stored in accordance with the relevant
data protection legislation in the member state. Patients are identified using
only their unique trial number and, if national legislation permits, their initials
and date of birth on the header section of the eRDC screens and in
correspondence between the applicable NCC and participating sites.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Cancer Research UK Clinical Trials Unit, University of Birmingham,
Mindelsohn Way, Birmingham B15 2TT, UK. 2Centre Léon Bérard, 28 rue
Laënnec, 69373 Lyon cedex 08, France. 3Société Française de Lutte contre les
Cancers et Leucémies de l’Enfant et de l’Adolescent (SFCE), 16 boulevard de
Bulgarie, 35203 Rennes, France. 4Groupe Sarcome Français - Groupe d’Etude
des Sarcome Osseux (GSF-GETO), 28 rue Laënnec, 69373 Lyon cedex 08,
France. 5Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805
Villejuif, France. 6Institut Curie, 26 Rue d’Ulm, 75005 Paris, France. 7Institute of
Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Avda. Manuel
Siurot, 41013 Sevilla, Spain. 8Hospital Universitario La Paz, 261 Paseo de la
Castellana, 28046 Madrid, Spain. 9European Organisation for Research and
Treatment of Cancer (EORTC), Avenue Mounier 83, B-1200 Brussels, Belgium.
10Our Lady’s Children’s Hospital, Cooley Rd, Dublin D12 N512, Ireland.
11Grupo Español de Investigación en Sarcomas (GEIS), Diego de León St,
47th 28006 Madrid, Spain. 12University College London, Gower Street,
London WC1E 6BT, UK. 13University College London Hospitals NHS
Foundation Trust, 250 Euston Road, London NW1 2PG, UK. 14Royal
Manchester Children’s Hospital, Oxford road, Manchester M13 9WL, UK.
15University Hospital Virgen del Rocio, Av. Manuel Siurot, 41013 Seville, Spain.
Received: 27 May 2019 Accepted: 21 December 2019
References
1. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M.
MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive
neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s
sarcoma and peripheral primitive neuroectodermal tumors from MIC2
expression and specific chromosome aberration. Cancer. 1991;67(7):1886–93.
2. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A. Translocation
involving chromosome 22 in Ewing’s sarcoma. A cytogenetic study of four
fresh tumors. Cancer Genet Cytogenet. 1984;12(1):21–5.
3. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The
Ewing family of tumors--a subgroup of small-round-cell tumors defined by
specific chimeric transcripts. N Engl J Med. 1994;331(5):294–9.
4. Dockhorn-Dworniczak B, Schäfer KL, Dantcheva R, Blasius S, Winkelmann W,
Strehl S, et al. Diagnostic value of the molecular genetic detection of the
t(11;22) translocation in Ewing’s tumours. Virchows Arch. 1994;425(2):107–12.
5. Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF, et al.
Overexpression of the pseudoautosomal gene MIC2 in Ewing‘s sarcoma and
peripheral primitive neuroectodermal tumor. Oncogene. 1990;5(7):1067–70.
6. Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir G. Chromosomal
translocation (11; 22) in cell lines of Ewing’s sarcoma. C R Seances Acad Sci
III. 1983;296(23):1101–3.
7. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA.
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med.
1984;311(9):584–5.
8. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O,
et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-
EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.
9. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al.
Safety assessment of intensive induction with vincristine, ifosfamide,
doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the
EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22–9.
10. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al.
Randomized controlled trial of interval-compressed chemotherapy for the
treatment of localized Ewing sarcoma: a report from the Children’s
Oncology Group. J Clin Oncol. 2012;30(33):4148–54.
11. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-
term efficacy and safety of zoledronic acid compared with pamidronate
disodium in the treatment of skeletal complications in patients with
advanced multiple myeloma or breast carcinoma: a randomized, double-
blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.
12. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men
with hormone-refractory prostate cancer: a systematic review of
randomized trials. Can J Urol. 2006;13(4):3180–8.
13. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van
Valen F. The bisphosphonate pamidronate is a potent inhibitor of Ewing’s
sarcoma cell growth in vitro. Anti-Cancer Drugs. 2003;14(9):767–71.
14. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary
bone tumor growth in Ewing sarcoma. Cancer. 2005;104(8):1713–20.
15. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, et al.
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing’s sarcoma
patients. Cancer Res. 2010;70(19):7610–9.
16. Tsiatis AA. The asymptotic joint distribution of the efficient scores test for
the proportional hazards model calculated over time. Biometrika. 1981;68(1):
311–5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Anderton et al. Trials           (2020) 21:96 Page 9 of 9
